Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 85.12M P/E - EPS this Y 42.40% Ern Qtrly Grth -
Income -79.19M Forward P/E -0.79 EPS next Y 37.90% 50D Avg Chg -17.00%
Sales 7.43M PEG - EPS past 5Y - 200D Avg Chg -48.00%
Dividend N/A Price/Book 0.68 EPS next 5Y - 52W High Chg -83.00%
Recommedations 1.90 Quick Ratio 2.41 Shares Outstanding 15.68M 52W Low Chg 10.00%
Insider Own 6.01% ROA -49.31% Shares Float 13.95M Beta 2.11
Inst Own 34.84% ROE -124.08% Shares Shorted/Prior 694.05K/792.64K Price 0.57
Gross Margin 100.00% Profit Margin - Avg. Volume 1,046,314 Target Price 24.30
Oper. Margin -7,406.19% Earnings Date Sep 5 Volume 732,715 Change -2.56%
About Affimed N.V.

Affimed N.V., a clinical-stage biopharmaceutical company, focuses on discovering and developing cancer immunotherapies in the United States and Germany. The company's lead product candidates include AFM13 that has completed Phase 2 clinical trial for CD30-positive lymphoma, Phase Ib clinical trial for hodgkin lymphoma, and completed Phase IIb clinical study for peripheral T-cell lymphoma; AFM24, a tetravalent, bispecific epidermal growth factor receptor, and CD16A-binding innate cell engager, which is in Phase IIa clinical trial for the treatment of advanced cancers; and AFM28, an innate cell engager (ICE), which is in preclinical development for the treatment acute myeloid. It develops AFM32, an ICE candidate that is in preclinical development for the treatment of solid tumors. It has collaboration with Artiva Biotherapeutics to develop the combination of acimtamig and AlloNK; license and strategic collaboration agreement with Roivant Sciences Ltd. to develop and commercialize novel ICE molecules, including AFM32, in oncology; and strategic collaboration agreement with Genentech for the development of certain product candidates, which includes novel NK cell engager-based immunotherapeutics to treat multiple cancers. The company was formerly known as Affimed Therapeutics B.V. and changed its name to Affimed N.V. in October 2014. Affimed N.V. was founded in 2000 and is headquartered in Mannheim, Germany.

Affimed N.V. News
12/17/24 Affimed Shares Fall 32% on Clinical Update
12/17/24 Affimed Reports Positive Clinical Update on AFM24/Atezolizumab Combination Therapy in Non-Small Cell Lung Cancer (NSCLC)
12/09/24 Affimed Reports Promising Phase 1 Efficacy and Safety Data for AFM28 in Relapsed/Refractory Acute Myeloid Leukemia (R/R AML)
12/09/24 Affimed to Host Investor Conference Call Highlighting Clinical Data from AFM24 in Combination with Atezolizumab in Non-Small Cell Lung Cancer
12/08/24 Affimed Announces Positive Results Demonstrating Safety and Efficacy of Acimtamig and AlloNK® Combination in Relapsed/Refractory Classical Hodgkin Lymphoma (R/R cHL) Patients
12/06/24 AFMD Stock Down Despite FDA's RMAT Status for Lymphoma Therapy
12/06/24 FDA RMAT status for Affimed and Artiva’s lymphoma combo therapy
12/05/24 Affimed Announces Acimtamig and AlloNK® Combination Granted Regenerative Medicine Advanced Therapy (RMAT) Designation by the U.S. Food and Drug Administration (FDA)
11/19/24 Is Affimed N.V. (AFMD) the Best German Stock to Buy Now?
11/15/24 Affimed NV (AFMD) Q3 2024 Earnings Call Highlights: Navigating Financial Challenges with ...
11/14/24 Affimed N.V.: Q3 Earnings Snapshot
11/14/24 Affimed Reports Third Quarter 2024 Financial Results & Business Update
11/06/24 Affimed to Report Third Quarter 2024 Financial Results & Corporate Update on November 14, 2024
11/05/24 Ultragenyx (RARE) Reports Q3 Loss, Tops Revenue Estimates
11/05/24 Affimed Announces Acceptance of Three Abstracts at the 2024 ASH Annual Meeting Including an Oral Presentation Underscoring Advancing Clinical Pipeline in Leukemia and Lymphoma
10/24/24 683 Capital Management, LLC Expands Stake in Affimed NV
09/10/24 Affimed to Present at the Cantor Global Healthcare Conference 2024
09/05/24 Affimed N.V.: Q2 Earnings Snapshot
09/05/24 Affimed Reports Second Quarter 2024 Financial Results & Business Update
09/04/24 Affimed Appoints New CEO, Shares Fall on Leadership Change
AFMD Chatroom

User Image TIGHTSTOPLOSS Posted - 1 day ago

$AFMD Strap in 🚀

User Image madi1004 Posted - 2 days ago

$AFMD Let us see where we will go before the end of 2024!

User Image TIGHTSTOPLOSS Posted - 2 days ago

$AFMD It’s Time Ladies $1.50 in No Time

User Image Slambucket Posted - 2 days ago

$AFMD - My WAG: GC Cell and Affimed will announce something in January. Emphasis on WAG

User Image Aurum81 Posted - 2 days ago

$AFMD Bought a first position 🍀

User Image Wellorganized Posted - 4 days ago

$AFMD the goal right now is to accumulate as much $AFMD at these prices! Need 8000 shares to get to 20k total shares.

User Image deathknight Posted - 5 days ago

$AFMD this stock is completely a conviction play for me. The momentum is horrible as well as all tech indicators. There's no point trading the stock but I do see the value in the science and would be happy to put bet in the stock -- it will end with 0 or 100x. I will ride it to the very end.

User Image ItsAGreatDay Posted - 5 days ago

$AFMD Too old to cry … AFMD drops $1.00 past week and up a whopping $0.04 today when the overall market is taking off! Can’t catch a ride whatsoever!!!!!

User Image PLATINUM_TRADES Posted - 6 days ago

$AFMD what's going on here.. Ignore the newbies this looks to pop soon. If you're with me.. Ima get u in near bottom be patient🥊🥊📢📢

User Image newton3921 Posted - 6 days ago

$AFMD this stock is totally done - reverse split is inevitable

User Image Aurum81 Posted - 6 days ago

$AFMD Partnerships with Genentech, Affivant (Roivant), Artiva, RMAT status, own platform and all this at cash level as well as RSI 14. That screams for a positive correction 🍀

User Image TheTarkioTrader Posted - 6 days ago

$AFMD what a shocker still garbage

User Image Luckiest_Man_Alive Posted - 6 days ago

$AFMD 🤝✌️👌❤️🕊️

User Image deathknight Posted - 6 days ago

$AFMD The problem of the share price is that the institutional holding is not even 30%. Too many shares are in retailers hands which adds a lot of volatility and FUD. But at this price range, the risk/reward will attract big buyers especially so since the general market is finally cooling off. Biotech industry as a whole is depressed too much and due a significant recovery.

User Image TIGHTSTOPLOSS Posted - 6 days ago

$AFMD We Are 🪑 In At $1.22 Average. Would Love $1.00 Average…

User Image deathknight Posted - 1 week ago

@laguna2 Not necessarily, they are targeting R/R patients, which is tricky since many patients might have developed strong resistance to any treatment available. Nobody knows how this drug will perform in untreated patients. If it does decently well, it could be viable. But in any case, $AFMD doesn't have the capital to push it through PhIII trial -- they have to sell it. IMO, it's the ROCK platform worth buying for the buyers.

User Image deathknight Posted - 1 week ago

$AFMD retailers here simply don't understand that the most valuable asset for $afmd is not its clinical pipelines but the ICE platform. This is essentially a bona fide CAR-T alternative. This company will be acquired for its platform. Pipelines are just for validating ICE platform and this is exactly why they chose refractory/relapsed patients chorts, which otherwise makes zero sense.

User Image deathknight Posted - 1 week ago

$AFMD there any other small biotech/pharma dedicatedly developing drugs for refractory/pre-treated cancer patients?

User Image laguna2 Posted - 1 week ago

@dhovekamp42 The analysis on dosage dependence on a small cohort has to be very noisy since it was further subdivided into 4 quadrants to do some dosage regression. It is a difficult position to negotiate any reasonable financing to further the research on 720mg. As I thought prior, the whole pipeline has to be sold as a package to minimize risk to a buyer or there will be no takers IMO $afmd

User Image laguna2 Posted - 1 week ago

$AFMD On a stand alone basis, AFM24 is dead and at best on life support IMO. Thoughts?

User Image NaldoH Posted - 1 week ago

$AFMD I don’t think this drop is justified, even if some are disappointed with the recent clinical results—which, to be fair, weren’t terrible. The decline is more likely due to massive tax-loss harvesting, a common trend that often triggers rebounds early in the new year. With the company funded through 2025, this could be an excellent opportunity to take a position and ride the recovery in the months ahead.

User Image ItsAGreatDay Posted - 1 week ago

$AFMD Facts supporting how analyst don’t know anything more than people on this board hype to know. For instance, HC Wainwright has a buy on AFMD with a target of $7.00. Wells Fargo says $11.00. And those perspectives was issued yesterday and today. Yet today, AFMD IS down another 15% to $1.29. Ridiculous market! Oh, yes, as someone will likely say that’s 12 months from now. True. But if they (analysts) were even close to a reasonable analysis, the market would know it too, and the price would not be dropping like it has; it was $6.00 this time last year.

User Image deathknight Posted - 1 week ago

$AFMD Added several hundreds more to my already very heavy bag. Just place some dots here for folks to connect: 1. why the company developed AFM24 targeting refractory/heavily pretreated patients? This is a very small population with high bar to hit. Normally small biotech target large patient population with huge TAM (total available market) for their first drugs. 2. Why Roche/atezolizumab instead of Merck/Keytruda? They had collaboration with Merck for AFM13. 3. Roche/Genentech made a 5.1 Billion deal with $AFMD back in 2018. Could be just strange coincidence or in bears' mind, extreme stupidity of the leadership. But I do believe there's something else here.

User Image JJFOYT Posted - 1 week ago

$AFMD Didn’t Roche just invest millions of dollars into Affimed?

User Image JJFOYT Posted - 1 week ago

$AFMD Ha! Just my luck. Should have waited to average down some.

User Image BioRich Posted - 1 week ago

$BIOA Since I love transparency, here's the list of my most recent investments. These are investments, not trades so not worried about short-term red, just happy to get in at the prices I did: BIOA $GPCR $AFMD $RVPH $BOLD. Think each of these has very solid long-term potential and will be winners in both the short-term and long-term. Follow/Subscribe for more suggestions and perspective. Would love to hear yours. That's how we find these gems. Let's make some money. Cheers!

User Image alecsalaur198 Posted - 1 week ago

$AFMD I added

User Image deathknight Posted - 1 week ago

$AFMD wow, seems MM are pricing in the company go BK this week.

User Image zahnan Posted - 1 week ago

I can't think of a worse biotech company than $AFMD... oh yeah, $ADAP. I wonder what they have in common *wink wink*

User Image TheTarkioTrader Posted - 1 week ago

$AFMD what a shocker it’s still garbage

Analyst Ratings
HC Wainwright & Co. Buy Nov 15, 23
Cantor Fitzgerald Overweight Sep 25, 23
Cantor Fitzgerald Overweight Sep 12, 23
Cantor Fitzgerald Overweight Sep 7, 23
Truist Securities Buy Aug 11, 23
HC Wainwright & Co. Buy Aug 11, 23
HC Wainwright & Co. Buy Jun 5, 23
HC Wainwright & Co. Buy May 24, 23
Stifel Hold Mar 24, 23